MANIJEH GOLDBERG, PH.D., M.B.A., M.S. — CHIEF EXECUTIVE OFFICER
Manijeh is the Founder and CEO of Privo Technologies. She has over 20 years of experience in the biomedical industry, in large companies and startups (one was acquired for $475M). Manijeh is an expert in product development from concept to market. She has successfully lobbied to get Privo’s lead product into a large NIH funded clinical study. Additionally, Manijeh is driving the execution of Privo’s pipeline products. Manijeh holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan School of Management, an MS in Computer Science and Mathematics and a BS in Engineering.
Dan Geffken, MBA — SENIOR FINANCIAL ADVISER
Dan has over 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. Over the course of his career, Daniel has raised nearly $2 billion in equity and debt securities for life science companies. He holds a BS from The Wharton School, University of Pennsylvania, and a MBA from Harvard Business School.
EDWARD GARMEY, M.D. — INTERIM CHIEF MEDICAL OFFICER
A former academic hematologist-oncologist at Memorial Sloan-Kettering Cancer Center, Edward has served as CMO for leading private and public biopharmaceutical companies during his 15 years in the industry. Prior to a transition into consulting in 2015, Dr. Garmey served as Chief Medical Officer and Senior Vice President at Cerulean Pharma where he oversaw the initiation of multi-national clinical trials for multiple drug programs and helped lead the company’s successful $67 MM IPO. Dr. Garmey is an alumnus of Harvard and New York Universities and completed his medical training at New York’s Mount Sinai Medical Center, the Children’s Hospital of Los Angeles, and Sloan-Kettering.
SAM GOLDBERGER, MD, MBA – SR. CLINICAL MONITOR
Sam is a well-known reconstructive and plastic surgeon with significant experience in the removal of squamous cell carcinoma and other epithelium tumors. Sam received his medical doctorate degree from the Albert Einstein College of Medicine in New York. He holds an MBA from MIT Sloan School of Management and a BS from MIT’s School of Biology. Sam has been practicing as a reconstructive surgeon since 1991 and has performed thousands of surgical procedures. In addition to his expertise in medicine, Sam is well-experienced in innovation, entrepreneurship, and growing successful business.
BRUCE SUNSTEIN, JD — INTELLECTUAL PROPERTY
Bruce is a patent and IP strategist for market leaders and innovators in diverse industries including pharmaceuticals, biotechnology, bioinformatics, and medical devices. He is also an experienced expert witness, an arbitrator, in intellectual property disputes. Bruce was selected by his peers for inclusion in the Best Lawyers in America in the fields of Patent Law and Intellectual Property-Litigation. Bruce is the founder of Sunstein LLP in Boston.
RUTHANNA COSTELLO — DIRECTOR OF CLINICAL RESEARCH
Ms. Costello is a seasoned health care professional with a diverse therapeutic background and leadership experience in clinical trial development. She has been managing studies for Sanofi-Aventis, Roche, and Abbott for over 20 years with increasing responsibilities. Ruthanna has been responsible for managing and effectively aligning clinical teams with appropriate institutions and providing oversight and focus on conducting human studies while ensuring patient safety, data integrity, and regulatory compliance. She Is an expert in complex clinical studies such as oncology and diabetes from early phase I trials to phase IV and NDA.
SCIENTIFIC & MEDICAL ADVISORS
NISHANT AGRAWAL, M.D.
Nishant Agrawal, MD, is the director of Head and Neck Surgical Oncology at the University of Chicago Medicine. Dr. Agrawal specializes in the management of patients with benign and malignant tumors of the head and neck. His work has achieved international recognition in the field of head and neck surgical oncology, and head and neck cancer genetics. Prior to joining the University of Chicago, Dr. Agrawal was an associate professor at Johns Hopkins University.
John Ripple founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development, and capital fundraising activities. He previously served as CEO of 5 venture-backed biotech companies, including Exonics Therapeutics (acquired by Vertex), Virdante Pharmaceuticals (acquired by Momenta), and Syntonix Pharmaceuticals (acquired by Biogen). Mr. Ripple also held positions in business development, entrepreneur-in-residence, medical device marketing, and management consulting. He started his career as an aerospace engineer at NASA. He currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), on the Board of Directors and Treasurer of the Children’s Melanoma Prevention Foundation, and as an advisor to the MIT Deshpande Center for Technological Innovation. Mr. Ripple received a BS in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.
JAMES DEMETROULAKOS, M.D., FACS
Dr. Demetroulakos is Chief of Otolaryngology/ Head and Neck Surgery at the North Shore Medical Center and Attending Staff at Mass General Hospital and Mass Eye and Ear Infirmary. He is an emeritus staff at Harvard Medical school and the Uniformed Services School of the Health Sciences. James received his medical and undergraduate degrees from Brown University through their seven-year med program.
BHARAT YARLAGADDA, MD
Bharat Yarlagadda, MD is the director of the Head and Neck Cancer Center of the Lahey Cancer Institute in Burlington, MA. His clinical practice specializes in the care of patients with benign and malignant tumors of the head and neck, including robotic surgery of the head and neck and microvascular reconstruction. He serves on numerous quality and safety committees at Lahey Hospital and Medical Center, as well as an elected member of the Medical Executive Committee. He is an assistant professor of Otolaryngology-Head and Neck Surgery at Boston University School of Medicine, with a research focus on quality outcomes and surgical simulation.